CHMP says yes to Novartis's Jakavi, BMS/AZ's Forxiga and Takeda's Rienso
This article was originally published in Scrip
Three new drugs have this month won a green light from the European Medicine Agency's Committee for Medicinal Products for Human Use, while two others were again rebuffed.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.